All In Biotech

NDA 213931 · Ardelyx INC

Xphozah

Tenapanor Hydrochloride · Oral

Novel

Last checked: Nov 19, 2026Latest source record: Jun 16, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2023

Oct 17, 2023

Approved uses

1

Original approval plus efficacy supplements

Registered trials

38

15 Phase 3, 2 recruiting

FAERS reports

23

18 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jun 27, 2025.

XPHOZAH is indicated to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy. XPHOZAH is a sodium hydrogen exchanger 3 (NHE3) inhibitor indicated to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy ( 1 ).

Mechanism: Tenapanor is a locally acting inhibitor that targets the sodium/hydrogen exchanger 3 (NHE3), an antiporter expressed on the apical surface of the epithelium of the small intestine and colon. Inhibition of NHE3 by tenapanor results in reduced sodium absorption and decreased phosphate absorption by reducing phosphate permeability through the paracellular pathway.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Oct 17, 2023 Original approval · Type 10 - New Indication Submitted as Distinct NDA - Not Consolidated NovelLetterLabelReview
3 products under this application
  • XPHOZAH · TENAPANOR HYDROCHLORIDE EQ 30MG BASE · TABLET, ORAL · Prescription
  • XPHOZAH · TENAPANOR HYDROCHLORIDE EQ 10MG BASE · TABLET, ORAL · Discontinued
  • XPHOZAH · TENAPANOR HYDROCHLORIDE EQ 20MG BASE · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Tenapanor" as an intervention, any sponsor and status, largest first.

All 38 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • nausea3
  • anaemia2
  • asthenia2
  • cough2
  • covid-192
  • decreased appetite2
  • diarrhoea2
  • drug ineffective2
  • drug ineffective for unapproved indication2
  • fatigue2
  • gastrointestinal disorder2
  • pre-existing condition improved2

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20212
20232
20244
20256
20269

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Xphozah (Tenapanor HCl)

2024 spending

$122M

Beneficiaries

9,953

34,525 claims

Per beneficiary

$12,208

$48.01 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$1,338,817
2024$121,506,333

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 40 on PubMed

Sponsor: Ardelyx INC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.